Dr. Corey Langer Discusses Erlotinib in Advanced NSCLC
I have an unusually enjoyable piece of DD to share w/ you. It is a rare pleasure to find that your due diligence carries you into the path of a remarkably talented celebrity, but such is this tale. It remains one of my primary reasons for staying long behind EXEL. It is a wonderful story of courage and determination.
Google this: "Zheng Cao Mezzo Soprano Lung Cancer xl-184".
For starters, you are looking for an ABC news article dated 11/11/2010. Complete with streaming video, this a wonderful expository piece on an incredible turnaround story of a relatively young operatic diagnosed w/ NSCLC. As remarkable as is the story, so is the documented fast-acting effect of xl-184... and the commentary by Stanford clinician Dr Heather Wakelee. This story has been followed by a variety of news sources over the past couple years - the more you look, the more you'll find.
For instance, you can easily find that Zheng's diagnosis is EGFR positive.
Although I realize that a single success does not make the entire case, this story makes such a compelling case for Cabo in a post-erlotinib setting...I couldn't resist sharing it once again. Zheng is indeed a remarkable woman to proactively share her story with all who would care to listen.
If you get the opportunity - listen to her sing. Absolutely amazing...